213 related articles for article (PubMed ID: 22496772)
1. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
2. Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors.
Bruder JT; Chen P; Semenova E; Thomas CA; Konovalova S; Ekberg G; Ettyreddy D; McVey D; Gall JG; King CR; Brough DE
J Virol; 2013 Sep; 87(17):9661-71. PubMed ID: 23824800
[TBL] [Abstract][Full Text] [Related]
3. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
5. Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectors.
Teigler JE; Penaloza-MacMaster P; Obeng R; Provine NM; Larocca RA; Borducchi EN; Barouch DH
Clin Vaccine Immunol; 2014 Aug; 21(8):1137-44. PubMed ID: 24943382
[TBL] [Abstract][Full Text] [Related]
6. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
7. A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.
Fonseca JA; Cabrera-Mora M; Kashentseva EA; Villegas JP; Fernandez A; Van Pelt A; Dmitriev IP; Curiel DT; Moreno A
PLoS One; 2016; 11(4):e0154819. PubMed ID: 27128437
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5.
Abe S; Okuda K; Ura T; Kondo A; Yoshida A; Yoshizaki S; Mizuguchi H; Klinman D; Shimada M
J Gene Med; 2009 Jul; 11(7):570-9. PubMed ID: 19391169
[TBL] [Abstract][Full Text] [Related]
9. Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.
Gu L; Farrow AL; Krendelchtchikov A; Matthews QL
J Vis Exp; 2015 May; (99):e52655. PubMed ID: 25993057
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
[TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon.
Xue C; Tian X; Li X; Zhou Z; Su X; Zhou R
Virus Res; 2014 Apr; 183():67-74. PubMed ID: 24518297
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection.
Bradley RR; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(1):625-9. PubMed ID: 22072776
[TBL] [Abstract][Full Text] [Related]
13. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
[TBL] [Abstract][Full Text] [Related]
14. New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model.
Limbach K; Stefaniak M; Chen P; Patterson NB; Liao G; Weng S; Krepkiy S; Ekberg G; Torano H; Ettyreddy D; Gowda K; Sonawane S; Belmonte A; Abot E; Sedegah M; Hollingdale MR; Moormann A; Vulule J; Villasante E; Richie TL; Brough DE; Bruder JT
Malar J; 2017 Jul; 16(1):263. PubMed ID: 28673287
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
[TBL] [Abstract][Full Text] [Related]
16. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.
Chmielewska AM; Naddeo M; Capone S; Ammendola V; Hu K; Meredith L; Verhoye L; Rychlowska M; Rappuoli R; Ulmer JB; Colloca S; Nicosia A; Cortese R; Leroux-Roels G; Balfe P; Bienkowska-Szewczyk K; Meuleman P; McKeating JA; Folgori A
J Virol; 2014 May; 88(10):5502-10. PubMed ID: 24599994
[TBL] [Abstract][Full Text] [Related]
17. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
18. The VP1 G-H loop hypervariable epitope contributes to protective immunity against Foot and Mouth Disease Virus in swine.
Fernandez-Sainz I; Gavitt TD; Koster M; Ramirez-Medina E; Rodriguez YY; Wu P; Silbart LK; de Los Santos T; Szczepanek SM
Vaccine; 2019 Jun; 37(26):3435-3442. PubMed ID: 31085001
[TBL] [Abstract][Full Text] [Related]
19. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
[TBL] [Abstract][Full Text] [Related]
20. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.
Tian X; Su X; Li X; Li H; Li T; Zhou Z; Zhong T; Zhou R
PLoS One; 2012; 7(7):e41381. PubMed ID: 22848478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
